MX362446B - Factores de coagulacion de accion prolongada y metodos de produccion de los mismos. - Google Patents

Factores de coagulacion de accion prolongada y metodos de produccion de los mismos.

Info

Publication number
MX362446B
MX362446B MX2014009910A MX2014009910A MX362446B MX 362446 B MX362446 B MX 362446B MX 2014009910 A MX2014009910 A MX 2014009910A MX 2014009910 A MX2014009910 A MX 2014009910A MX 362446 B MX362446 B MX 362446B
Authority
MX
Mexico
Prior art keywords
methods
producing same
long
coagulation factors
acting coagulation
Prior art date
Application number
MX2014009910A
Other languages
English (en)
Other versions
MX2014009910A (es
Inventor
Eyal Fima Udi
Hart Gili
Original Assignee
Opko Biologics Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=48983616&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MX362446(B) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority claimed from US13/372,540 external-priority patent/US8759292B2/en
Application filed by Opko Biologics Ltd filed Critical Opko Biologics Ltd
Publication of MX2014009910A publication Critical patent/MX2014009910A/es
Publication of MX362446B publication Critical patent/MX362446B/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/59—Follicle-stimulating hormone [FSH]; Chorionic gonadotropins, e.g.hCG [human chorionic gonadotropin]; Luteinising hormone [LH]; Thyroid-stimulating hormone [TSH]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P41/00—Drugs used in surgical methods, e.g. surgery adjuvants for preventing adhesion or for vitreum substitution
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475—Growth factors; Growth regulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/745—Blood coagulation or fibrinolysis factors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/24—Follicle-stimulating hormone [FSH]; Chorionic gonadotropins, e.g. HCG; Luteinising hormone [LH]; Thyroid-stimulating hormone [TSH]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
    • A61K38/482—Serine endopeptidases (3.4.21)
    • A61K38/4846—Factor VII (3.4.21.21); Factor IX (3.4.21.22); Factor Xa (3.4.21.6); Factor XI (3.4.21.27); Factor XII (3.4.21.38)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/31—Fusion polypeptide fusions, other than Fc, for prolonged plasma life, e.g. albumin

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Endocrinology (AREA)
  • Zoology (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Hematology (AREA)
  • Genetics & Genomics (AREA)
  • Toxicology (AREA)
  • Biochemistry (AREA)
  • Diabetes (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Reproductive Health (AREA)
  • Dermatology (AREA)
  • Surgery (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Glass Compositions (AREA)

Abstract

Se describen polipéptidos que comprenden al menos un péptido de extremo carboxi (CTP) de gonadotropina coriónica unida al extremo carboxi pero no al extremo amino de un factor de coagulación y polinucleótidos que codifican los mismos. También se describen composiciones farmacéuticas que comprenden los polipéptidos y polinucleótidos de la invención y métodos de utilización y producción de los mismos.
MX2014009910A 2012-02-14 2013-02-05 Factores de coagulacion de accion prolongada y metodos de produccion de los mismos. MX362446B (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US13/372,540 US8759292B2 (en) 2006-02-03 2012-02-14 Long-acting coagulation factors and methods of producing same
PCT/IL2013/050107 WO2013121416A1 (en) 2012-02-14 2013-02-05 Long-acting coagulation factors and methods of producing same

Publications (2)

Publication Number Publication Date
MX2014009910A MX2014009910A (es) 2015-09-28
MX362446B true MX362446B (es) 2019-01-18

Family

ID=48983616

Family Applications (3)

Application Number Title Priority Date Filing Date
MX2019000708A MX393997B (es) 2012-02-14 2013-02-05 Factores de coagulacion de accion prolongada y metodos de produccion de los mismos.
MX2014009910A MX362446B (es) 2012-02-14 2013-02-05 Factores de coagulacion de accion prolongada y metodos de produccion de los mismos.
MX2022008807A MX2022008807A (es) 2012-02-14 2014-08-14 Factores de coagulacion de accion prolongada y metodos de produccion de los mismos.

Family Applications Before (1)

Application Number Title Priority Date Filing Date
MX2019000708A MX393997B (es) 2012-02-14 2013-02-05 Factores de coagulacion de accion prolongada y metodos de produccion de los mismos.

Family Applications After (1)

Application Number Title Priority Date Filing Date
MX2022008807A MX2022008807A (es) 2012-02-14 2014-08-14 Factores de coagulacion de accion prolongada y metodos de produccion de los mismos.

Country Status (22)

Country Link
EP (4) EP4488289A3 (es)
JP (2) JP6242819B2 (es)
KR (3) KR102630953B1 (es)
CN (2) CN104427994A (es)
AU (3) AU2013219935B2 (es)
BR (1) BR122021004014B1 (es)
CA (1) CA2870621C (es)
CL (2) CL2014002183A1 (es)
CO (1) CO7131365A2 (es)
DK (2) DK2822576T3 (es)
EA (2) EA201790960A3 (es)
ES (3) ES2665319T3 (es)
HU (1) HUE053068T2 (es)
IL (2) IL264959B (es)
MX (3) MX393997B (es)
MY (1) MY172539A (es)
NO (1) NO2920022T3 (es)
PE (1) PE20142290A1 (es)
PL (2) PL3326642T3 (es)
PT (1) PT3791890T (es)
SG (1) SG11201404836QA (es)
WO (1) WO2013121416A1 (es)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9249407B2 (en) 2006-02-03 2016-02-02 Opko Biologics Ltd. Long-acting coagulation factors and methods of producing same
WO2013121416A1 (en) * 2012-02-14 2013-08-22 Prolor Biotech Inc. Long-acting coagulation factors and methods of producing same
US12203113B2 (en) 2009-07-09 2025-01-21 Opko Biologics Ltd. Long-acting coagulation factors and methods of producing same
US9663778B2 (en) 2009-07-09 2017-05-30 OPKO Biologies Ltd. Long-acting coagulation factors and methods of producing same
US20150158926A1 (en) 2013-10-21 2015-06-11 Opko Biologics, Ltd. Long-acting polypeptides and methods of producing and administering same
WO2016092550A2 (en) * 2014-12-10 2016-06-16 Opko Biologics Ltd. Methods of producing long acting ctp-modified polypeptides
EP3988113A1 (en) * 2015-06-19 2022-04-27 OPKO Biologics Ltd. Long-acting coagulation factors and methods of producing same
AU2016301303B2 (en) 2015-08-03 2021-10-07 Bioverativ Therapeutics Inc. Factor IX fusion proteins and methods of making and using same
BR112019000610A2 (pt) * 2016-07-11 2019-07-02 Opko Biologics Ltd fator vii de coagulação de longa ação e métodos de produção do mesmo
CN107759694B (zh) 2016-08-19 2023-01-13 安源医药科技（上海）有限公司 双特异性抗体及其制备方法与用途
US11123438B2 (en) 2016-08-19 2021-09-21 Ampsource Biopharma Shanghai Inc. Linker peptide for constructing fusion protein
CN106279437B (zh) * 2016-08-19 2017-10-31 安源医药科技（上海）有限公司 高糖基化人凝血因子viii融合蛋白及其制备方法与用途
US11981718B2 (en) 2020-05-27 2024-05-14 Ampsource Biopharma Shanghai Inc. Dual-function protein for lipid and blood glucose regulation

Family Cites Families (39)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NL154600B (nl) 1971-02-10 1977-09-15 Organon Nv Werkwijze voor het aantonen en bepalen van specifiek bindende eiwitten en hun corresponderende bindbare stoffen.
NL154598B (nl) 1970-11-10 1977-09-15 Organon Nv Werkwijze voor het aantonen en bepalen van laagmoleculire verbindingen en van eiwitten die deze verbindingen specifiek kunnen binden, alsmede testverpakking.
NL154599B (nl) 1970-12-28 1977-09-15 Organon Nv Werkwijze voor het aantonen en bepalen van specifiek bindende eiwitten en hun corresponderende bindbare stoffen, alsmede testverpakking.
US3901654A (en) 1971-06-21 1975-08-26 Biological Developments Receptor assays of biologically active compounds employing biologically specific receptors
US3853987A (en) 1971-09-01 1974-12-10 W Dreyer Immunological reagent and radioimmuno assay
US3867517A (en) 1971-12-21 1975-02-18 Abbott Lab Direct radioimmunoassay for antigens and their antibodies
NL171930C (nl) 1972-05-11 1983-06-01 Akzo Nv Werkwijze voor het aantonen en bepalen van haptenen, alsmede testverpakkingen.
US3850578A (en) 1973-03-12 1974-11-26 H Mcconnell Process for assaying for biologically active molecules
US3935074A (en) 1973-12-17 1976-01-27 Syva Company Antibody steric hindrance immunoassay with two antibodies
US3996345A (en) 1974-08-12 1976-12-07 Syva Company Fluorescence quenching with immunological pairs in immunoassays
US4034074A (en) 1974-09-19 1977-07-05 The Board Of Trustees Of Leland Stanford Junior University Universal reagent 2-site immunoradiometric assay using labelled anti (IgG)
US3984533A (en) 1975-11-13 1976-10-05 General Electric Company Electrophoretic method of detecting antigen-antibody reaction
US4098876A (en) 1976-10-26 1978-07-04 Corning Glass Works Reverse sandwich immunoassay
US4879219A (en) 1980-09-19 1989-11-07 General Hospital Corporation Immunoassay utilizing monoclonal high affinity IgM antibodies
US5011771A (en) 1984-04-12 1991-04-30 The General Hospital Corporation Multiepitopic immunometric assay
DE3421468A1 (de) 1984-06-08 1985-12-19 Dr. Rentschler Arzneimittel Gmbh & Co, 7958 Laupheim Lipidnanopellets als traegersystem fuer arzneimittel zur peroralen anwendung
US4666828A (en) 1984-08-15 1987-05-19 The General Hospital Corporation Test for Huntington's disease
US4683202A (en) 1985-03-28 1987-07-28 Cetus Corporation Process for amplifying nucleic acid sequences
US4801531A (en) 1985-04-17 1989-01-31 Biotechnology Research Partners, Ltd. Apo AI/CIII genomic polymorphisms predictive of atherosclerosis
DE122007000007I1 (de) 1986-04-09 2007-05-16 Genzyme Corp Genetisch transformierte Tiere, die ein gewünschtes Protein in Milch absondern
US4873316A (en) 1987-06-23 1989-10-10 Biogen, Inc. Isolation of exogenous recombinant proteins from the milk of transgenic mammals
US5272057A (en) 1988-10-14 1993-12-21 Georgetown University Method of detecting a predisposition to cancer by the use of restriction fragment length polymorphism of the gene for human poly (ADP-ribose) polymerase
US6225449B1 (en) * 1991-10-04 2001-05-01 Washington University Hormone analogs with multiple CTP extensions
AU648020B2 (en) 1989-02-21 1994-04-14 Washington University Modified forms of reproductive hormones
US5792460A (en) * 1989-02-21 1998-08-11 Washington University Modified glycoprotein hormones having a CTP at the amino terminus
US5464764A (en) 1989-08-22 1995-11-07 University Of Utah Research Foundation Positive-negative selection methods and vectors
US5192659A (en) 1989-08-25 1993-03-09 Genetype Ag Intron sequence analysis method for detection of adjacent and remote locus alleles as haplotypes
US5281521A (en) 1992-07-20 1994-01-25 The Trustees Of The University Of Pennsylvania Modified avidin-biotin technique
US5541110A (en) 1994-05-17 1996-07-30 Bristol-Myers Squibb Cloning and expression of a gene encoding bryodin 1 from Bryonia dioica
US7795210B2 (en) * 2001-10-10 2010-09-14 Novo Nordisk A/S Protein remodeling methods and proteins/peptides produced by the methods
CN1245510C (zh) * 2003-09-25 2006-03-15 复旦大学 长效重组组织因子途径抑制物及其制备方法
US7553941B2 (en) 2006-02-03 2009-06-30 Modigene Inc Long-acting polypeptides and methods of producing same
US8048849B2 (en) * 2006-02-03 2011-11-01 Modigene, Inc. Long-acting polypeptides and methods of producing same
US8476234B2 (en) * 2006-02-03 2013-07-02 Prolor Biotech Inc. Long-acting coagulation factors and methods of producing same
US8759292B2 (en) * 2006-02-03 2014-06-24 Prolor Biotech, Llc Long-acting coagulation factors and methods of producing same
TWI465247B (zh) * 2008-04-11 2014-12-21 Catalyst Biosciences Inc 經修飾的因子ｖｉｉ多肽和其用途
MX2011000847A (es) * 2008-08-06 2011-02-25 Novo Nordisk Healthcare Ag Proteinas conjugadas con eficacia prolongada in vivo.
WO2013121416A1 (en) 2012-02-14 2013-08-22 Prolor Biotech Inc. Long-acting coagulation factors and methods of producing same
ES2882890T3 (es) * 2012-11-20 2021-12-03 Opko Biologics Ltd Método para aumentar el volumen hidrodinámico de polipéptidos mediante la unión a péptidos carboxi terminales de la gonadotrofina

Also Published As

Publication number Publication date
HK1205460A1 (en) 2015-12-18
MX2022008807A (es) 2022-08-11
BR112014020198A2 (pt) 2018-05-15
EA201790960A3 (ru) 2018-01-31
ES2855133T3 (es) 2021-09-23
EP2822576B1 (en) 2018-01-10
DK3326642T3 (da) 2021-02-22
KR20200063274A (ko) 2020-06-04
MX2019000708A (es) 2020-09-02
EA201790960A2 (ru) 2017-09-29
MX2014009910A (es) 2015-09-28
AU2013219935A1 (en) 2014-09-25
EP2822576A1 (en) 2015-01-14
CL2017002233A1 (es) 2018-05-11
AU2013219935B2 (en) 2016-02-04
CA2870621C (en) 2022-08-09
AU2017219044A1 (en) 2017-09-14
CA2870621A1 (en) 2013-08-22
EP2822576A4 (en) 2015-11-25
MY172539A (en) 2019-11-30
KR102630953B1 (ko) 2024-01-29
PL3326642T3 (pl) 2021-06-14
AU2017219044B2 (en) 2019-05-30
CN109535245A (zh) 2019-03-29
KR102310704B1 (ko) 2021-10-08
JP2018065815A (ja) 2018-04-26
EA028578B1 (ru) 2017-12-29
EP4488289A3 (en) 2025-03-19
SG11201404836QA (en) 2014-12-30
CN104427994A (zh) 2015-03-18
BR122021004014B1 (pt) 2022-12-27
EP3326642A1 (en) 2018-05-30
NO2920022T3 (es) 2018-06-09
EP3791890A1 (en) 2021-03-17
HUE053068T2 (hu) 2021-06-28
EA201491519A1 (ru) 2014-12-30
AU2016202829B2 (en) 2017-05-25
AU2016202829A1 (en) 2016-05-19
PE20142290A1 (es) 2015-01-15
IL282121A (en) 2021-05-31
JP2015508771A (ja) 2015-03-23
CO7131365A2 (es) 2014-12-01
KR102118729B1 (ko) 2020-06-05
WO2013121416A1 (en) 2013-08-22
JP6510002B2 (ja) 2019-05-08
PL3791890T3 (pl) 2025-04-14
ES3010346T3 (en) 2025-04-02
ES2665319T3 (es) 2018-04-25
EP4488289A2 (en) 2025-01-08
KR20140134673A (ko) 2014-11-24
JP6242819B2 (ja) 2017-12-06
IL282121B (en) 2022-06-01
MX393997B (es) 2025-03-24
PT3791890T (pt) 2025-02-14
IL264959B (en) 2021-08-31
KR20210125595A (ko) 2021-10-18
EP3326642B1 (en) 2020-11-25
EP3791890B1 (en) 2024-11-13
DK2822576T3 (en) 2018-04-16
CL2014002183A1 (es) 2015-01-09

Similar Documents

Publication Publication Date Title
MX2022008807A (es) Factores de coagulacion de accion prolongada y metodos de produccion de los mismos.
MX2021012106A (es) Factores de coagulacion de accion prolongada y metodos de produccion de los mismos.
AU2019201173B2 (en) Novel polypeptides
WO2016203482A3 (en) Long-acting coagulation factors and methods of producing same
MY167814A (en) Long-acting oxyntomodulin variants and methods of producing same
EA201590994A1 (ru) Способ увеличения гидродинамического объема полипептида путем присоединения карбоксиконцевого пептида гонадотропина
WO2013152351A3 (en) Fusion polypeptides and methods of use thereof
WO2013009627A3 (en) Factor viii chimeric and hybrid polypeptides, and methods of use thereof
MX2017006866A (es) Pares de unión para producción de péptidos.
MX2021000030A (es) Metodos y composiciones que utilizan polipeptidos variantes klotho.
WO2012158964A3 (en) Improved peptide pharmaceuticals for osteoporosis
WO2013142859A3 (en) Fusion proteins of superfolder green fluorescent protein and use thereof
GB2517354A (en) Hydrochloride salt of peptide and its use in combination with other peptides for immunotherapy
WO2013181404A3 (en) COMPOSITIONS AND METHODS FOR PEPTIDE EXPRESSION AND PURIFICATION USING A TYPE lll SECRETION SYSTEM
MX360187B (es) Uso de polipeptidos derivados de pedf para promover la regeneración de músculo o tendón o arteriogénesis.
MX2024014446A (es) Factor vii de coagulacion de accion prolongada y metodos para producir el mismo
ZA201603274B (en) Recombinant peptide vaccines against ticks, and nucleotide sequences coding for the recombinant peptides
IL189000A0 (en) Fusion peptides based on influenza hemagglutinin polypeptides
LV15035A (lv) Rekombinēta himēriska polipeptīda, kas satur melanokortīna otrā tipa receptoru (MC2R) un melanokortīnu receptoru palīgproteīnu (MRAP), kDNS secības, un tās izmantošana aktīvo vielu testēšanai un terapeitiskiem mērķiem
MY155338A (en) Novel insulin derivatives having an extremely delayed time-action profile
IL238904B (en) A method for increasing the hydrodynamic volume of a polypeptide by linking peptides through their carboxyl end to gonadotropin

Legal Events

Date Code Title Description
FG Grant or registration